Open an account

SeaStar Medical Holding

ICU · NASDAQ

$3.05−$0.06 (−1.93%)TodayMarket closed ·
Prev close $3.11

About ICU

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 17 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).

Employees
17
Headquarters
Denver, Colorado
Listed
Jan 26, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
seastarmedical.com

ICU key statistics

Market cap
13.44M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
231.69K
Volume
107.58K
Open price
$3.11
High today
$3.15
Low today
$2.94
52 Week high
$6.50
52 Week low
$2.07

SeaStar Medical Holding (ICU) at a glance

SeaStar Medical Holding (ICU) last traded at $3.05, with a market cap of 13.44M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.94 and $3.15. The current price is 3.7% above the day's low and 3.2% below its high.

Volume so far is 107.58K shares, below the average of 231.69K shares a day.

Over the past year SeaStar Medical Holding has ranged from $2.07 to $6.50, and now sits 22% of the way up that range.

SeaStar Medical Holding met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.91 per share against an estimate of -$0.9797.

The average analyst price target is $10.20, 234.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $10.20
Low
$8.08
Now
$3.05
High
$12.60

ICU earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 20.8% on average.

  1. Q3 FY24: reported -$11.00 per share against an estimate of -$11.41
  2. Q4 FY24: reported -$9.00 per share against an estimate of -$8.99
  3. Q1 FY25: reported -$4.40 per share against an estimate of -$5.25
  4. Q2 FY25: reported -$1.80 per share against an estimate of -$4.34
  5. Q3 FY25: reported -$1.30 per share against an estimate of -$1.51
  6. Q4 FY25: reported -$0.80 per share against an estimate of -$1.07
  7. Q1 FY26: reported -$0.90 per share against an estimate of -$0.8333
  8. Q2 FY26: reported -$0.91 per share against an estimate of -$0.9797

ICU news

  • Full Transcript: SeaStar Medical Holding Q1 2026 Earnings Call

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Why Oracle Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

  • A Glimpse of SeaStar Medical Holding's Earnings Potential

  • Press releaseGlobe Newswire

    SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

  • Avi Kapoor

    Nasdaq Down Over 1%; US Initial Jobless Claims Fall

  • SeaStar Medical Announces That Independent DSMB Recommends Continuing NEUTRALIZE-AKI Pivotal Trial Of Its Selective Cytopheretic Device Therapy For Adult Patients With Acute Kidney Injury Requiring Continuous Renal Replacement Therapy

Similar companies

Companies in the same industry as SeaStar Medical Holding

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.